Symptoms during chemotherapy in colorectal cancer patients
Colorectal cancer (CRC) patients experience several physical and psychological co-occurring symptoms, but little is known about symptom variation during chemotherapy cycles. Therefore, the aims were (1) to assess the occurrence and severity of frequently occurring symptoms (worrying, lack of energy, numbness/tingling, nausea, and pain) at multiple time points during chemotherapy, (2) to investigate differences in symptom trajectories between chemotherapy groups, and (3) to determine whether selected patient and clinical characteristics are associated with symptom severity throughout the treatment trajectory.
In total, 120 CRC patients receiving chemotherapy with curative or palliative intent completed the Memorial Symptom Assessment Scale (MSAS), Self-Administered Comorbidity Questionnaire (SCQ-19), and Karnofsky Performance Status (KPS) scale eight times, during two cycles of chemotherapy and 3 and 6 months after enrolment. Data were analyzed using linear mixed models for repeated measures to assess the effects of selected variables on outcomes over time.
The patients experienced greatest symptom severity in the days following the administration of chemotherapy; these were lack of energy, numbness/tingling (oxaliplatin group), and nausea. Palliative patients reported significantly higher pain scores compared with curative patients over time, whereas the severity of worrying decreased over time in both treatment groups. Age, sex, educational level, performance status, treatment intent and type of chemotherapy were significantly associated with symptom severity throughout the chemotherapy trajectory.
Clinicians can use these findings to identify and inform patients about risk for more severe symptom burden, in order to offer supportive care at the right time during the chemotherapy treatment.
KeywordsColorectal neoplasm Chemotherapy Symptoms Trajectory Longitudinal Memorial Symptom Assessment Scale
The authors thank the patients for their valuable contribution to this study. Furthermore, we thank the study nurse Ms. Kolstad, and Oslo University Hospital, Oslo, for their help and facilitation, Mr. Pripp for his statistical advice at the early study process, and Mr. Horgmo and Ms. Ellefsen of the Medical Photography and Illustration Service, University of Oslo, for the valuable graphic support.
The Institute of Health and Society, Faculty of Medicine, Nursing Science, Oslo University supported this study, with additional grants from The Norwegian Nurses Organization.
Compliance with ethical standards
The Regional Ethical Committee (2009/1451), the Hospital Privacy Ombudsman, and the institutional review board at Oslo University Hospital approved the study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Tantoy IY, Cooper BA, Dhruva A et al (2018) Changes in the occurrence, severity, and distress of symptoms in patients with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manag 55(3):808–834Google Scholar
- 6.Kristensen A, Solheim TS, Amundsen T et al (2017) Measurement of health-related quality of life during chemotherapy—the importance of timing. Acta Oncol 56(5):737–745Google Scholar
- 8.Foltran L, Aprile G, Pisa FE, Ermacora P, Pella N, Iaiza E, Poletto E, Lutrino SE, Mazzer M, Giovannoni M, Cardellino GG, Puglisi F, Fasola G (2014) Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. Support Care Cancer 22(9):2527–2533CrossRefGoogle Scholar
- 12.Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefGoogle Scholar
- 14.Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119(24):4333–4340CrossRefGoogle Scholar
- 19.Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092CrossRefGoogle Scholar
- 25.Schneider A, Kotronoulas G, Papadopoulou C, McCann L, Miller M, McBride J, Polly Z, Bettles S, Whitehouse A, Kearney N, Maguire R (2016) Trajectories and predictors of state and trait anxiety in patients receiving chemotherapy for breast and colorectal cancer: results from a longitudinal study. Eur J Oncol Nurs 24:1–7CrossRefGoogle Scholar
- 26.Astrup GL, Hofso K, Bjordal K et al (2017) Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol 56(3):462–470Google Scholar
- 30.Brandenbarg D, Korsten J, Berger MY, Berendsen AJ (2018) The effect of physical activity on fatigue among survivors of colorectal cancer: a systematic review and meta-analysis. Support Care Cancer 26(2):393–403Google Scholar
- 32.Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefGoogle Scholar